Company Directory > MedTech > Hematology-Oncology Associates of Central New York
Hematology-Oncology Associates of Central New York (HOACNY) is a prominent, physician-owned private medical practice specializing in the diagnosis and treatment of cancer and blood disorders. Founded in 1982, the organization operates multiple comprehensive cancer centers across the Central New York region, including facilities in East Syracuse, Camillus, and Auburn. The practice provides a multidisciplinary approach to patient care, offering services such as medical oncology, radiation oncology (including CyberKnife and TrueBeam technology), infusion services, diagnostic imaging, laboratory services, and cancer genetics counseling. HOACNY is highly integrated into the community oncology landscape, maintaining active participation in over 100 clinical research trials through affiliations with the National Cancer Institute and other national cancer centers.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:
Industry:Medical Devices
Sub-Industry:Oncology/Hematology Clinical Practice
SIZE & FINANCIALS
Employees:201-500
Founded:1982
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Active Trials:115
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:National Cancer Institute (Clinical research), Cancer Connects (Non-profit patient support)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Jennifer Pichoske - CEO
Scientific Founders:John J. Gullo, MD, Santo M. DiFino, MD
LINKS
Website:hoacny.com
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Hematology-Oncology Associates of Central New York and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hematology-Oncology Associates of Central New York. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.